📰 Immunic News
Page 10 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
June 28, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Industry and Scientific Conferences in July 28.06.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic to Participate in Industry and Scientific Conferences in July NEW YORK, June 28,...
June 15, 2022
Issuer: Immunic, Inc. / Key word(s): Scientific publication/Study results Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting
June 15, 2022
NEW YORK, June 15, 2022 /PRNewswire/ -- Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic... | June 15, 2022
June 8, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
June 8, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June 08.06.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Scientific, Industry and Investor Confer...
June 6, 2022
Immunic, Inc. (NASDAQ:IMUX – Get Rating) CFO Glenn Whaley bought 3,500 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was acquired at an average price of $3.04 per share, for a total transaction of $10,640.00. Following the acquisition, the chief financial officer now directly owns 12,568 shares in the […]
June 6, 2022
Immunic, Inc. (NASDAQ:IMUX – Get Rating) CEO Daniel Vitt purchased 5,000 shares of Immunic stock in a transaction on Friday, June 3rd. The stock was bought at an average price of $3.10 per share, for a total transaction of $15,500.00. Following the completion of the acquisition, the chief executive officer now owns 368,877 shares in […]
June 3, 2022
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that […]
June 2, 2022
Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis
June 2, 2022
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...